@Article{,
AUTHOR = {Kylea Potvin, Eric Winquist},
TITLE = {Hormone-refractory prostate cancer: a primer  for the primary care physician},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {15},
YEAR = {2008},
NUMBER = {Suppl.4},
PAGES = {14--20},
URL = {http://www.techscience.com/CJU/v15nSuppl.4/63110},
ISSN = {1488-5581},
ABSTRACT = {<b>Objective:</b> To provide a current and evidence-based clinical review of practical value to primary care physicians encountering men with hormone-refractory prostate cancer (HRPC) in their practice.<br/>
<b>Methods:</b> Evidence-based narrative review by two expert clinicians incorporating results of systematic reviews and randomized trials whenever available.<br/>
<b>Results:</b> HRPC represents the final common pathway to death from prostate adenocarcinoma, the single most prevalent cancer in Canadian men. However, primary care physicians will not encounter these patients with a frequency adequate to develop confidence in their care. HRPC is defined by progressive disease despite castration, and biologically is a characterized by androgen hypersensitivity. It is important to understand that HRPC is a disease spectrum ranging from asymptomatic patients with only a rising prostatic-specific antigen (PSA) level and a prognosis measured in years to extremely symptomatic patients with widespread metastases requiring end-of-life care. Numerous effective management options are now available for HRPC and are selected based on the phase of the disease natural history, and patient comorbidities and preferences.<br/>
<b>Conclusions:</b> Men with HRPC have therapeutic options that can improve and maintain both the quality and quantity of their lives. A co-management approach including a medical oncologist and the patient's urologist and primary care physician is preferred.},
DOI = {}
}